| Trial ID # | NCT03797326 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Lenvatinib, Pembrolizumab |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 31 ovarian; median 3 prior therapies; 25 Pt-R |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, evaluated per RECIST |
| Efficacy | ORR: 32% (n=31) Exploratory analysis, Pt-status, prior Bevacizumab: |
| Clinically Significant Adverse Events | Serious AE: 1 death (hypovolemic shock) |
| Conclusion | Pembrolizumab+lenvatinib demonstrates encouraging efficacy and manageable safety in patients with heavily pretreated ovarian cancer, including those with prior platinum failure and those with previous bevacizumab exposure |
| Reference | Gonzales-Martin A et al. Efficacy and Safety of Lenvatinib Plus Pembrolizumab in Patients with Previously Treated Ovarian Cancer in the Multicohort Phase 2 LEAP-005 Study. IGCS (2020) Plenary I, abstract 2 Gonzales-Martin A et al. Table from abstract |